![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Under the partnership to develop NFL-101, the company’s drug candidate Tobacco leaf protein for smoking cessation, for the Indian market with Themis Medicare Ltd., will purchase Active Pharmaceutical Ingredient (API) from NFL Biosciences.
Lead Product(s): Tobacco Leaf Protein
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Recipient: NFL Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 05, 2022